KEAP1 and neoplasm: Ricciuti et al. [53] demonstrated that KEAP1 and STK11 mutations generate an immune-exclusionary tumor microenvironment, limiting PD-(L)1 response in NSCLC; therefore, combining metabolic or redox modulation with immune checkpoint blockade could restore sensitivity.